- Home
- MTH vs GALT Comparison
MTH vs GALT Comparison
Compare MTH & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTH
- GALT
- Stock Information
- Founded
- MTH 1985
- GALT 2000
- Country
- MTH United States
- GALT United States
- Employees
- MTH N/A
- GALT N/A
- Industry
- MTH Homebuilding
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- MTH Consumer Discretionary
- GALT Health Care
- Exchange
- MTH Nasdaq
- GALT Nasdaq
- Market Cap
- MTH 5.1B
- GALT 232.3M
- IPO Year
- MTH 1988
- GALT N/A
- Fundamental
- Price
- MTH $76.56
- GALT $4.64
- Analyst Decision
- MTH Buy
- GALT Strong Buy
- Analyst Count
- MTH 9
- GALT 3
- Target Price
- MTH $87.25
- GALT $6.00
- AVG Volume (30 Days)
- MTH 879.3K
- GALT 357.1K
- Earning Date
- MTH 10-28-2025
- GALT 11-12-2025
- Dividend Yield
- MTH 2.25%
- GALT N/A
- EPS Growth
- MTH N/A
- GALT N/A
- EPS
- MTH 8.78
- GALT N/A
- Revenue
- MTH $6,216,250,000.00
- GALT N/A
- Revenue This Year
- MTH N/A
- GALT N/A
- Revenue Next Year
- MTH $6.59
- GALT N/A
- P/E Ratio
- MTH $8.73
- GALT N/A
- Revenue Growth
- MTH N/A
- GALT N/A
- 52 Week Low
- MTH $59.27
- GALT $0.73
- 52 Week High
- MTH $106.99
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- MTH 48.71
- GALT 54.36
- Support Level
- MTH $74.71
- GALT $4.35
- Resistance Level
- MTH $80.00
- GALT $6.55
- Average True Range (ATR)
- MTH 2.45
- GALT 0.46
- MACD
- MTH -0.68
- GALT -0.07
- Stochastic Oscillator
- MTH 18.44
- GALT 21.07
About MTH Meritage Homes Corporation
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.